Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be ...
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight ...
Zacks Investment Research on MSN
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of ...
Amgen Inc. delivered strong operational performance across the board in 2025, and you can see that in the breadth of our business. Three of these, Repatha, Evenity, and TestSpire, all grew by more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results